Furthermore, in the realm of therapeutic biomarkers, pre-clinical studies have demonstrated the efficacy of targeting MALAT-1 using RNA interference in prostate cancer, yielding successful results in xenograft models (Wang et al. 2017). Here, MALAT1 is linked to prostate carcinoma.